| PD-1/PD-L1抑制剂在尿路上皮癌治疗中的研究进展 |
| |
| 引用本文： | 王华超1,穆中一2,刘世博2,叶 鹏2,胡 滨2. PD-1/PD-L1抑制剂在尿路上皮癌治疗中的研究进展[J]. 现代肿瘤医学, 2020, 0(19): 3434-3437. DOI: 10.3969/j.issn.1672-4992.2020.19.034 |
| |
| 作者姓名： | 王华超1 穆中一2 刘世博2 叶 鹏2 胡 滨2 |
| |
| 作者单位： | 1.大连医科大学，辽宁 大连 116044；2.中国医科大学肿瘤医院，辽宁省肿瘤医院，辽宁 沈阳 110042 |
| |
| 基金项目： | National Natural Science Foundation of China(No.81702526）；国家自然科学基金（编号:81702526） |
| |
| 摘 要： | 近年来，随着人们对肿瘤免疫生物学认识的不断深入，针对免疫检查点抑制的系统免疫疗法在尿路上皮癌领域得到了广泛的探索和临床应用。程序性细胞死亡受体1(programmed death 1，PD-1)及其配体(programmed death ligand 1，PD-L1)是机体免疫活性的重要负性调节因子，可防止正常组织和自身免疫功能的破坏。迄今为止，美国食品和药物管理局(Food and Drug Administration，FDA)已批准了可阻断PD-1(Pembrolizumab和Nivolumab)或PD-L1(Atezolizumab、Durvalumab和Avelumab)的五种免疫检查点抑制剂，根据在相关临床试验中观察到的持久的治疗反应和可控的安全性，用于局部晚期或转移性尿路上皮癌的一线或二线治疗。本文就PD-1/PD-L1抑制剂在尿路上皮癌中的研究进展作一综述。
|
| 关 键 词： | 尿路上皮癌 PD-1抑制剂 PD-L1抑制剂 免疫治疗 |
Research progress of PD-1/PD-L1 inhibitors in the treatment of urothelial carcinoma |
| |
| Wang Huachao1,Mu Zhongyi2,Liu Shibo2,Ye Peng2,Hu Bin2. Research progress of PD-1/PD-L1 inhibitors in the treatment of urothelial carcinoma[J]. Journal of Modern Oncology, 2020, 0(19): 3434-3437. DOI: 10.3969/j.issn.1672-4992.2020.19.034 |
| |
| Authors: | Wang Huachao1 Mu Zhongyi2 Liu Shibo2 Ye Peng2 Hu Bin2 |
| |
| Affiliation: | 1.Dalian Medical University，Liaoning Dalian 116044，China；2.Cancer Hospital of China Medical University，Liaoning Cancer Hospital ＆ Institute，Liaoning Shenyang 110042，China. |
| |
| Abstract: | In recent years，with the deepening of people's understanding of tumor immunobiology，systematic immunotherapy for immune checkpoint suppression has been widely explored and applied in the field of urothelial carcinoma(UC).Programmed death 1(PD-1)and its programmed death ligand 1(PD-L1)are important negative regulators of immune activity，which can prevent the destruction of normal tissue and autoimmune function.To date，the US Food and Drug Administration(FDA)has approved five immune checkpoint inhibitors that block PD-1(Pembrolizumab，Nivolumab) or PD-L1(Atezolizumab，Durvalumab and Avelumab).First-line or second-line treatment is used for locally advanced or metastatic UC，based on long-lasting therapeutic response and controllable safety observed in relevant clinical trials.This article reviews the progress of PD-1/PD-L1 inhibitors in UC. |
| |
| Keywords: | urothelial carcinoma PD-1 inhibitor PD-L1 inhibitor immunotherapy |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
